# Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.

> **NCT03469050** · PHASE2,PHASE3 · TERMINATED · sponsor: **Alfasigma S.p.A.** · enrollment: 193 (actual)

## Conditions studied

- Diverticulitis

## Interventions

- **DRUG:** Rifaximin delayed released 400mg Tablet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03469050
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-02
- **Primary completion:** 2020-12-22
- **Final completion:** 2020-12-22
- **Target enrollment:** 193 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2021-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469050, "Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03469050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*